Likewise, the use of single agent 2-CdA was determined by the oncologist to be relevant because of the endocrinology concern regarding monitoring his glucose/insulin using conventional prednisone and vinblastine treatment for multifocal LCH in the setting of BMI > 50. This evidence concerns the gene INS and Langerhans cell histiocytosis.